Mr Balaggan was appointed as a Consultant Ophthalmic Surgeon at New Cross Hospital in 2015 after completing the vast majority of his ophthalmic training at Moorfields Eye Hospital. He is currently Director of the Vitreo-retinal service, and Lead for Information Technology and Undergraduate Education at Wolverhampton Eye Infirmary. Mr Balaggan performs routine and complex cataract surgery in addition to vitreoretinal surgery including the treatment of retinal detachments, epiretinal membranes, macula holes and diabetic complications.
As a vitreoretinal surgeon, Mr Balaggan is referred complex cataract cases from his colleagues, locally and regionally. This includes both complex cataracts as well as complications of other surgeons ‘ procedures. Only vitreoretinal surgeons can deal with all possible unexpected and expected intraoperative complications arising from cataract surgery, which is very reassuring for your patient and yourselves.
Mr Balaggan performs exclusively micro-incision cataract surgery (2.2mm incision) which when compared with standard incision (2.75-3.2mm) surgery has the benefits of having a reduced recovery time, less induced astigmatism, less need for sutures and is potentially safer.
As Mr Balaggan is also a NHS Consultant, this provides important additional reassurance for private patients as he can route them to his NHS practice should this ever be required for existing or chronic conditions. This also is reassuring for yourselves as you will know that continuity of care can be provided for all the patients you refer to Mr Balaggan for cataract or vitreoretinal surgery, including self-pay patients and insured patients.
Mr Balaggan was also chosen by Moorfield Eye Hospital to be the Lead Investigator external Investigator for the prestigious FACT Clinical Trial which is an NHS-funded clinical trial evaluating the role of femtosecond laser-assisted cataract surgery for NHS patients. His site, recruited over a 100 patients for this study.
In addition to cataract surgery Mr Balaggan also offers a full range of vitreo-retinal surgery privately including vitrectomy for the removal of eye floaters. This procedure has been well studied in recent years and is a permanent treatment for floaters which can now be carried out more safely and effectively than before, and can be combined with cataract surgery if required.
Mr Balaggan is unique in being one of exceptionally few surgeons that have completed not just two years of prestigious high-volume Fellowships in Vitreoretinal Surgery, but also two years of subspecialist Fellowship training in Medical Retina, all at the internationally-renowned Moorfields Eye Hospital, London. This was in addition to his general ophthalmic training, which was also predominantly based at this Centre of Excellence and one of the world’s top Eye Hospitals.
Mr Balaggan obtained a PhD from University College London (ranked in the top five universities globally) developing state-of-the-art Gene Therapy for age-related macular degeneration as well as other retinal disorders. He has been awarded numerous prizes recognising his contribution to advancing frontiers in ophthalmology and for his teaching excellence. He is considered an expert in retinal medicine and surgery, and is often invited to lecture both nationally and internationally, teaching other retinal specialists.
Mr Balaggan has an outstanding track record in research and teaching. He spent four years full-time at University College London, under the guidance of internationally-awarded Professor Robin Ali, performing cutting-edge research developing novel retinal gene-based therapies for age-related macular degeneration and inherited retinal disorders.
Mr Balaggan was also a co-investigator in the world’s first gene therapy trial for an inherited retinopathy (New England Journal of Medicine 2008, 2015), and more recently a key investigator in the first randomised clinical evaluation of subconjunctival bevacizumab for new-onset corneal neovascularisation (British Journal of Ophthalmology, 2012). I co-designed and am the Principal Investigator in a new clinical trial based at Moorfields Eye Hospital, which will evaluate a novel radiotherapy device for the treatment of macular degeneration.